Description

Adults
For the treatment of the following uncomplicated and complicated infections caused by susceptible microorganisms, when oral antibiotic therapy is not possible or not reliable:
Urinary tract and kidney infections including cystitis, pyelonephritis
Lower respiratory tract infections including acute exacerbations of chronic bronchitis
Nosocomial pneumonia including hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
Acute sinusitis, middle ear infection (otitis media) and eye infections
Skin and skin structure infections
Septicemia
Intra-abdominal infections (the anaerobic component should be covered by an appropriate antibacterial agent) including infections of the gastrointestinal tract or of the biliary tract, peritonitis
Bone and joint infections including osteomyelitis
Genital infections including adnexitis, chronic bacterial prostatitis
To reduce the incidence or progression of inhalational anthrax following exposure to aerosolized Bacillus anthracis (ciprofloxacin serum concentrations achieved in humans serve as surrogate endpoint reasonably likely to predict clinical benefit and provide basis for this indication).
As an empirical therapy for febrile neutropenic patients
As a prophylaxis in infections or imminent risk of infection in patients whose immune system has been weakened (e.g., patients on immunosuppressants or have neutropenia)
For selective intestinal decontamination in immunosuppressed patients

Children and Adolescents:

Complicated urinary tract infections and pyelonephritis due to Escherichia coli in patients 1 to 17 years old.

Acute pulmonary exacerbations of cystic fibrosis associated with Pseudomonas aeruginosa infection in patients 5 to 17 years old

Inhalational anthrax (post-exposure)